SageView Advisory Group’s Roivant Sciences ROIV Stock Holding History

SageView Advisory Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-505	Closed	-$11K	–	2042
2025 Q4	$11K	Buy	+505	New	+$9.96K	﹤0.01%	1683

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SageView Advisory Group's ROIV Position: Q1 2026 in Review

SageView Advisory Group sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 505 shares — an estimated $11K sold.

SageView Advisory Group first reported a position in ROIV in Q4 2025 and held it in 1 quarter. The position peaked at $11K in Q4 2025. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

SageView Advisory Group reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 505 Roivant Sciences shares in Q1 2026, an estimated $11K.
SageView Advisory Group first reported a position in Roivant Sciences in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Roivant Sciences position peaked at $11K in Q4 2025.
444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.